NantKwest Signs Worldwide License Agreement with ProMab

Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate For Multiple Myeloma, With An Option For Up To Five Additional CAR Targeting Sequences.

ProMab and NantKwest recently launched a collaboration to develop BCMA CAR-NK cell development.

> Read more